Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.

Nat Med

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Published: October 2024

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-024-03348-1DOI Listing

Publication Analysis

Top Keywords

publisher correction
4
correction allogeneic
4
allogeneic cd5-specific
4
cd5-specific car-t
4
car-t therapy
4
therapy relapsed/refractory
4
relapsed/refractory t-all
4
t-all phase
4
phase trial
4
publisher
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!